In vivo changes in plasma acute phase protein levels in the rat induced by slow release of IL-1, IL-6 and TNF by Lewis, E. J. et al.
Research Paper
Mediators of Inflammation 1, 39-44 (1992)
ADMINISTRATION of large doses of cytokines by injection is
required to induce changes in acute phase protein levels.
Comparisons were made in the rat of the effects of admin-
istering recombinant human cytokines by injection with
continuous release from implanted osmotic minipumps.
Continuous release of interleukin-lfl (0.2-2.1 ng h -1) in-
duced dose-related changes in the plasma levels of albu-
min, seromucoid proteins, haptoglobin and caeruloplas-
min; interleukin-10 had similar effects but required higher
doses (2-21 ng h-l). Tumour necrosis factor (50 ng h-1)
only significantly increased seromucoid levels, whereas
IL-6 (3-30 ng h-1) induced haptoglobin and caeruloplas-
synthesis. This method provides a better technique for
studying the in rive effects of cytokines which may be
relevant to the release mechanisms in inflammation.
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Introduction
Acute phase proteins (APPs) are defined as those
proteins produced by the liver whose levels change
during the course of inflammation or trauma. 1’2
APP are heterogeneous in nature with different
physiological functions, protein synthesis and often
electrophoretic mobility and cannot be classified
under one simple chemical heading. APP include
proteins such as C-reactive protein, fibrinogen,
haptoglobin, caeruloplasmin, albumin etc. In man,
during the course of severe inflammation, levels of
CRP can increase up to 1 000-fold and fibrinogen
two- to three-fold. However, albumin levels can
decrease, thus specific APPs also have a variable
degree of change.
The change in levels of APPs has been shown to
correlate to the degree of inflammation in patients
with rheumatoid arthritis
3 and for this reason, APPs
are routinely used as markers of inflammation and
the effectiveness of drugs modifying arthritis. In the
early 1970s it was shown that a plasma-borne
mediator released from cells at the site of
inflammation altered the rate of liver synthesis of
the acute phase proteins.
4 This mediator was later
purified, defined as a cytokine and named
interleukin-1. Subsequently, a number of cytokines
involved in inducing changes in liver synthesis have
been identified, purified and cloned. The main
cytokines recognised as inducing changes in liver
synthesis of APPs are interleukin-1 (IL-1), inter-
leukin-6 (IL-6) and tumour necrosis factor (TNF).
All of these cytokines have been shown to induce
APP changes in cultured hepatocytes, hepatoma
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cells6’7 and also induce changes in the plasma levels
of animals after injection. 8’9 The concentrations of
the cytokines required to induce changes in APPs
in vivo have been much greater than those used in
vitro because of the short half-life of the cytokines
in blood. 1’11
In inflammatory conditions, release of the
cytokines is more likely to be continuous rather
than spasmodic, therefore to model these effects in
vivo a method of sustained release of the cytokines
is required. The aim of this study was to investigate
the effects of interleukin-lo on APP levels in the
rat after single and multiple injection and to
compare these effects with IL-I administered by
slow release from implanted osmotic minipumps.
Further studies were made using slow release of
recombinant human IL-lfl, TNFo and IL-6 in the
rat in order to determine the role of these cytokines
in the induction of individual APPs.
Materials and Methods
Animals: In all the experiments described, female,
Allen and Hanbury Hooded strain rats were used.
The rats weighed between 90 and 160g and were
aged between 8 and 12 weeks old. The animals were
provided with tap water and Spillers PCD diet ad
libitum throughout the experiment.
Collection ofplasma: Ether anaesthetized rats were bled
from the dorsal tail artery using a heparin rinsed
(Liquemine, Roche; 500 U/ml) 1 ml syringe fitted
with a 23G x 30 mm needle. Blood was collected
and transferred to a 1.5 ml eppendorf tube and
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centrifuged for 5 min at 1500 g in a MSE
microcentrifuge. Plasma was either stored at 4C if
analysed within 3 days or frozen at -20C to be
analysed at a later date.
Formulation of cytokines for administration: The re-
combinant human cytokines were kind gifts from
Dr P Lomedico, Hoffman La Roche, Nutley, New
York (rhlL-l and rhlL-lfl); Dr Hooculi, Hoffman
La Roche, Basel (rhTNF) and Professor W Fiers,
University of Ghent, Belgium (rhIL-6). In all
experiments the concentrations of the cytokines
required were achieved by diluting stock concentra-
tions with a sterile saline solution containing 0.2%
bovine serum albumin, which was used as a carrier
protein for the cytokine. Stock solutions were kept
frozen at --20C and thawed immediately before
use. The specific activity of the recombinant hu-
man cytokines were :- rhlL-l 2.1 x 10 U/mg;
rhlL-lfl 2.4 108U/mg; rhTNF--I.0 x 108
U/mg; and rhlL-6 3.1 108 U/mg as determined
by the appropriate cellular assays.
Administration of cytokines: Injections of rhIL-lcz were
made using dilutions of the stock solutions in 0.2%
bovine serum albumin and rats were injected with
2 ml kg of body weight -1. Alzet osmotic mini-
pumps (Model 2001; 1/,1 h-1) were filled in a sterile
air flow cabinet with the cytokine. Before the
pumps were implanted the rats were anaesthetized
and their backs shaved with animal clippers. A small
incision (10-15 mm) was made through the skin and
a pair of blunt ended scissors was inserted through
the incision on one side and the tissue connecting
the skin layer to the muscle body wall layer was
gently teased apart to form a channel of about 3 cm
wide to a depth of 3 cm. An osmotic minipump was
implanted through the incision to the end of the
channel on one side of the backbone. The incision
was then closed using two or three Michel clips
(6 mm) and the area swabbed with 1% Hibitane (R)
in 70% ethanol.
Assay ofplasma APP" Plasma obtained from the rats
was analysed using a Cobas-bio centrifugal analyser.
The methods used to assay APPs have been
previously described in detail12 but, in brief,
albumin levels were determined using the bromo-
cresol green dye binding assay;
13 seromucoid by
protein precipitation,
14 haptoglobin by the gen-
eration of peroxidase activity when bound to added
methaemoglobinlS and caeruloplasmin by its
oxidase activity using p-phenylenediamine.
16
Results
Effect of injected rhIL-la" Injections of rhIL-10 (6 ng g
of animal body weight-1) were made into groups of
five rats using a variety of routes of administration.
The animals were bled 24 h later. Haptoglobin
levels were significantly increased by injected
rhlL-l and this was independent of the route of
administration (Table 1). No effect of IL-1
administration was seen in plasma levels of
seromucoid. Seromucoid is a crude precipitation
fraction of glycosylated proteins which according
to our two-dimensional immunoelectrophoretic
studies is composed of zl acid glycoprotein, 1
cysteine protease inhibitor and possibly hemopexin.
Caeruloplasmin levels were unaffected whereas
albumin plasma levels were significantly reduced in
the groups of rats injected i.p. or i.v. but not s.c.
Dose response to rhIL-l administered s.c. The effect of
single s.c. doses of 2 and 6 ng g-1 of IL-I was
compared to the effect of 2ngg-
of IL-I
administered at 0, 2 and 4 h. Plasma was obtained
24 h after the initial injection. The multiple dose
was far more effective than the single dose with
greater changes in plasma levels of albumin,
seromucoid, haptoglobin and caeruloplasmin in the
multiple dosed rats (Table 2). Injection of IL-lcz
(6 ng g- s.c.) in both experiments (Tables 1 and 2)
induced different degrees of changes in haptoglobin
Table 1. Effect of injected rhlL-l on plasma APP levels in the rat
Substance Dose Route Albumin Seromucoid Haptoglobin Caeruloplasmin
administered (ng g-l) (g i-1) (g i-1) (g i_1) (g i_1)
Vehicle 29.3 + 0.24 3.9 + 0.27 0.21 + 0.02 0.66 + 0.01
IL-I 6 s.c. 28.6 _+ 0.44 4.4 -_.- 0.20 0.51 _+ 0.01 0.69 _+ 0.01
IL-I 6 i.p. 28.3 _+ 0.18 4.5 ___
0.25 0.47 _+ 0.01 0.68 +_ 0.02
IL-I 6 i.v. 27.7 _+ 0.24 4.3 _+ 0.15 0.44 _+ 0.05 0.69 _+ 0.02
Values represent the mean _+_ SE from groups of five rats. Significant changes in the levels of albumin (*p < 0.05,
**p < 0.01 were obtained from rats injected i.p. and i.v. respectively. Plasma was taken 24 h after injection. Administration
of IL-I by the different routes induced significant changes in haptoglobin level (*** p < 0.001) compared to vehicle
(0.2% albumin in saline i.p.) dosed rats by Student’s t-test (unpaired, two-tailed). Other values shown were not statistically
ditterent from the vehicle dosed group.
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Table 2. Effect of single and multiple injections of rhlL-1 on plasma APP levels in the rat
Substance Dose Number Albumin Seromucoid Haptoglobin Caeruloplasmin
administered (ng g-l) of doses (g 1-1 (g 1-1) (g 1-1) (g 1-1
Vehicle
IL-I
IL-I
IL-I
26.8 + 0.36 2.9 + 0.19 0.44 + 0.09 0.67 + 0.01
2 25.5 + 0.82 2.6 + 0.14 0.64 + 0.05 0.67 + 0.03
6 26.8 _+ 0.57 3.1 _+ 0.12 0.65 _+ 0.04 0.72 _+ 0.02
2 3 26.0 +_ 0.63 3.6 _+ 0.27 1.05 _+ 0.06 0.80 _+ 0.03
Values represent the mean 4- SE from groups of five rats. Significant changes in the levels of caeruloplasmin (*p < 0.05)
were obtained from rats injected s.c. at a single dose of 6 ng g-1. Plasma was taken 24 h after injection. Administration of
IL-I by multiple dose of 2 ngg -1 at 0.2 and 4 h induced significant changes in the levels of seromucoid (*p < 0.05),
haptoglobin (***p < 0.001) and caeruloplasmin (***p < 0.001) compared to vehicle (0.2% albumin in saline s.c.) dosed
rats by Student’s t-test (unpaired, two-tailed). Other values shown were not statistically different from the vehicle
dosed group.
and caeruloplasmin levels. The lack of significant
effect of IL-I on haptoglobin levels in the second
experiment may be explained by the higher levels
of haptoglobin in the vehicle dosed (control)
animals and greater variation as defined by the
standard error. Caeruloplasmin levels were statistic-
ally significantly raised in the second experiment but
not the first where the change in levels was 7% and
5% of the control levels respectively, therefore the
degree of change should be considered minor in
comparison to inflammation induced changes of
80-100% over control levels.
Osmotic minimump released rhIL- 10t: Alzet osmotic
minipumps (Model 2001) were filled with either
0.2% albumin as a vehicle control or concentrations
of rhlL-10 of up to 21 ng/1-1. The pumps were
implanted s.c. and allowed to release IL-I for
about 110 h (1/*1 h-l--top total dose 2.3/,g/rat).
Animals were bled on the fourth day after
implantation and the plasma analysed for APPs
(Table 3). This time schedule and doses were chosen
from preliminary experiments where it was shown
that the maximum increase in APP levels occurred
within 3 to 4 days after implantation and then the
APP levels decreased, possibly due to tolerance to
human IL-1. Implanting the minipump and cutting
through the rat skin produced a minor inflam-
matory reaction which induced a significant
increase in plasma levels of caeruloplasmin
compared to untreated rats. Minipumps administer-
ing 0.2 ng h-
of rhlL-10 had no effect on plasma
APP levels compared to animals with minipumps
containing vehicle. Only albumin levels were
reduced by 0.6 ng h
-1 of rhIL-10, higher doses of
2.1, 6.3 and 21 ng h-1 significantly altered the other
APPs in a dose related manner. It was noticed that
by day 4, a granuloma had formed around the
higher dose rhIL-10 pumps with or without a
collection of fluid/exudate. The amount of fluid
Table 3. Effect of osmotic minipump released rhlL-1 on plasma APP levels in the rat
Substance Dose AIbum in Seromucoid HaptogIob n CaeruIoplasm n
administered (ng h -1 (g 1-1 (g 1-1 (g 1-1 (g 1-1
Vehicle 35.9 + 0.89
No Minipump 38.2 _
0.55
IL-I 0.2 35.1 + 0.79
IL-I 0.6 33.4 + 0.48
5.6 + 0.37 1.05 + 0.04 0.76 + 0.02
5.6 _+ 0.51 1.01 _+ 0.07 0.68 _+ 0.02
5.5 + 0.28 1.07 + 0.05 0.73 + 0.02
5.0 + 0.21 1.11 + 0.03 0.80 + 0.02
IL-I 2.1 33.4 + 0.27 6.6 + 0.39 1.73 + 0.14 0.88 + 0.02
IL-1 e 6.3 28.9 _+ 0.39 9.3 _+ 0.20 1.96 _+ 0.10 0.93 _+ 0.04
IL-I 21 28.1 _+ 0.27 11.5 _+ 0.34 2.20 _+ 0.04 1.11 _
0.02
Values represent the mean 4- SE from groups of five rats. Group designated as vehicle were implanted with
Alzet osmotic minipumps containing 0.2% albumin in saline and releasing /1 h -1 The APP levels in plasma
were determined 4 days after implantation of the pumps. Rats dosed with vehicle alone from the minipumps
has significantly lower plasma levels of albumin (*p < 0.05) and greater levels of caeruloplasmin (*p < 0.05)
than non-implanted rats (no minimpump). Significant changes in the levels of albumin (*p < 0.05) were
obtained from rats administered with 0.6 ng h -1 Administration of IL-I at higher doeses of 2.1,6.3, and 21 n h
induced dose dependent changes in all the APPs measured, most of the changes were statistically significantly
different from the vehicle alone group (**p < 0.01 to ***p < 0.001 as determined by Student’s t-test (unpaired,
two-tailed). Other values shown were not statistically significantly different from the vehicle dosed group.
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within the granuloma and the granuloma weight
varied greatly between rats within each group,
therefore the exact volume or weight could not be
used as a parameter except for being present or
absent.
Dose response studies to cytokines released from minipumps:
The effects of recombinant human IL-I, IL-lfl,
IL-6 and TNFz released from implanted osmotic
minipumps on APP levels in the rat were studied
in separate dose response experiments. The effect of
the minipump released cytokine was compared to
minipump released 0.2% albumin and expressed as
a percentage. Implanted minipumps containing
0.2% albumin were used as a vehicle control because
of the minor inflammatory effect of implanting the
minipumps and because of the variation in base-line
levels of APPs. The maximal % changes shown for
IL-10 are consistent with the changes associated
with (adjuvant) inflammation.
12
Recombinant human interleukin-lfl was the most
potent cytokine tested with activity at 0.21 ng h
-1
where the cytokine significantly reduced levels of
albumin. At doses of 2.1 ng h
-1 interleukin-lfl
induced changes in the plasma levels of albumin,
seromucoid, haptoglobin and caeruloplasmin and
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FIG. Effect of osmotic minipump released cytokines on plasma APP in the rat. Figures show the change in individual APP levels in rats implanted
with osmotic minipumps containing either cytokines or vehicle (0.2% albumin in saline). The dotted line shows the base level of the APP as 0% in the
group of five rats implanted with osmotic minipumps containing the vehicle. All the effects of cytokine dosed rate (five rats/group) were corrected to
the vehicle group and change in APP levels expressed as a % change. The effects of IL-I (O-O); IL-lfl (--A--); IL-6 and TNF
(-’-I-’-) on plasma APP levels are shown after continuous release of the cytokines for 5 days. Statistical significance to the vehicle control group is
shown as *p < 0.05; **p < 0.01 and ***p < 0.001 according to Student’s t-test (unpaired; two-tailed).
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also produced a variable exudate inside the
granuloma in three out of five rats. Interleukin-10
had similar effects to those seen with IL-lfl, but
rhlL-lfl was ten times more active than rhlL-10 in
this rat model (Fig. 1).
At the highest dose tested (30 ng h-1) rhlL-6
significantly increased haptoglobin and caerulo-
plasmin levels by 40% and 60% respectively when
compared with the IL-1 induced levels. IL-6 did
not produce granulomas or exudate fluid around
the pump.
Recombinant human turnout necrosis factor at
doses up to 50 ng h
-1 did not induce granuloma
formation or any exudate. The only change seen in
the APP levels was a slight increase (20%) in the
levels of seromucoid at the highest dose tested,
50 ng h-1 (Fig. 1).
Discussion
Administration of rhIL-10 by single injection
with doses up to 600 ng/rat induced changes in the
levels of APPs measured 24 h after injection, but
these changes were not pronounced when com-
pared with changes seen in inflammation. Admin-
istering rhlL-10 by multiple dose was more effective
than the equivalent single dose with a significant
change in levels of seromucoid, haptoglobin and
caeruloplasmin. Similar results have been shown by
De Jong et al., who demonstrated that i.p.
injections of rhlL-1 at doses of 500 #g at 0, 2 and
4h increased liver mRNA levels of zl acid
glycoprotein and transferrin but decreased albumin
and fibrinogen. Also sustained short term release of
rhlL-1 (150#g i.v.) by a 6 h infusion in rats
increased 01 acid glycoprotein but did not alter
plasma levels of albumin, 01 cysteine protease
inhibitor or 02 macroglobulin.
17
Administration of IL-10 by sustained release
from the osmotic minipump (6.3 ng h-) produced
a greater response than a single injection (6 ng g-)
even though the total dose administered was similar
(approximately 600 ng/rat). Implantation of mini-
pumps had only a minor effect on APP levels
measured 4 days after implantation, therefore the
enhanced activity of the cytokine must be
dependent on the continuous release overcoming
the rate of cytokine degradation. Few authors have
used osmotic minipumps to administer cytokines
when studying changes in APP levels; Gordeuk et
al.,
8 have studied the et:fects of rhIL-1 on iron
metabolism in mice and could not show any
difference between single bolus and perfused IL-1
on the degree of decreased iron levels.
8 The dose
related eects of rhlL-10 on APPs shows that the
most sensitive APP of the number measured was
albumin whose levels were decreased with admin-
istration of 0.6 ng h -1. This sensitivity of the liver
synthesis of albumin to low dose cytokines may
have a beneficial eect in vivo by reducing albumin
synthesis before allowing the liver to increase
synthesis of other proteins.
Separate comparative studies using osmotic
minipumps to administer IL-10, IL-lfl, IL-6 and
TNF0 were performed to determine which
cytokine(s) modulated the synthesis of specific
APPs in an in vivo model. In this model,
implantation of the minipump caused a mild
inflammation which induced a weak acute phase
response (as seen with the increase in caerulo-
plasmin in the previous experiment), thus the
levels of APP inducing cytokines and corticoster-
oids in the blood were probably raised above
normal background levels. Changes in levels of the
APPs were therefore compared to the APP levels
from animals implanted with osmotic minipumps
containing 0.2% albumin as a vehicle control.
Albumin levels were significantly reduced by
both IL-10 and IL-lfl but not IL-6 or TNF0. This
efl:ect of IL-1 is probably via a direct mediation
because IL-1 can induce TNF0 and IL-6 release
from cells19’ which could alter liver APP synthesis.
In vitro studies by Baumann et al.,
6 indicate that IL-1,
TNF0 and IL-6 act to decrease albumin production
by hepatocytes, and this data is supported by Andus
et al.
21 Administration of IL-1 by repeat i.p. doses
in vivo reduced albumin synthesis; IL-6 did not
induce such a pronounced reduction.
9 Gresser et
a/.,
22 have demonstrated a weak reduction in
albumin levels after single administration of
rmTNF. Co-administration of dexamethasone with
cytokines in human hepatoma cell cultures has been
shown to reverse hypoalbuminia associated with
cytokines,
6 therefore endogenous corticosteroids
may act to inhibit IL-6 and TNF albumin lowering
effects but not the effect of IL-1.
The diflerence in potency between IL-10 and
IL-lfl in the rat has been previously reported by
Ferreira et al.,
23 who measured IL-1 induced algesia
in rats and found that IL-lfl was 100 times more
potent than IL-1. Most in vitro experiments do
show similar activity for both types of IL-1,
therefore the difference in effect of the two
recombinant human IL-l’s may relate to a
metabolic effect or distribution of the cytokine in
the rat.
Seromucoid levels were increased by both IL-1
IL-lfl and TNF0q although TNF0 only caused a
minor increase in seromucoid levels (20% of total
response to IL-1). Seromucoid is a crude
precipitation fraction of glycosylated proteins such
as 0 acid glycoprotein, 0 cysteine proteinase
inhibitor and hemopexin. Interleukin-1 has been
shown to increase 0 acid glycoprotein levels both
in vitro24 and in vivo.
2 Interleukin-6 had no eect on
seromucoid levels which differs from the findings
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of Markinovic et a/.,
25 but is similar to those of
Geiger et a/.,
24 who measured liver mRNA levels of
acute phase proteins after i.p. injection of 800 ng of
IL-6 but this dose only increased fibrinogen to a
similar extent to that induced by injection of
turpentine. In the same study 01 acid glycoprotein
and 1 cysteine protease inhibitor were only
marginally increased by IL-6.
Haptoglobin levels were raised by IL-I, IL-lfl
and IL-6. In vitro studies using hepatocytes have
shown that IL-6 acts in synergy with IL-1 and
glucocorticoids to induce both haptoglobin mRNA
and protein.
26 In vivo studies have shown that IL-6
and IL-1 both induce haptoglobin levels in the
rat.25,27
Caerulosplasmin is not a widely studied APP
because levels of this protein are only doubled in
inflammatory conditions. In these experiments
caeruloplasmin levels were increased by IL-1 and
IL-6 administration with IL-6 inducing 60% of the
change seen with IL-1, thus IL-6 may be the main
inducer of caeruloplasmin.
Both IL-10 and IL-lfl produced a granulomatous
response around the minipump, a similar finding
has been shown by Dunn et a/.,
28 who studied the
effects of slow release cytokines from implanted
ethylene vinyl acetate sponges. The fluid sur-
rounding the pumps contained large numbers of red
blood cells and PMNs which is consistent with the
reported effects of IL-lfl in inducing a Shwartzman-
like reaction in rabbit skin after intradermal
injections.
29 The infiltration of PMNs into the skin
has also been reported to occur in rabbit skin after
i.d. injection of IL-lfl and IL-10 at doses of 0.1 ng
3
and 2.5 ng/injection site respectively.
31 No granulo-
matous response was seen with implanted osmotic
minipumps containing vehicle, IL-6 or TNF0.
Overall, the results suggest that in vivo in the rat
where there would be continuous release of IL-1,
IL-6, TNF and glucocorticoids at basal levels, IL-6
may be the major inducer of caeruloplasmin and act
in synergy with IL-1 and glucocorticoids to induce
haptoglobin. IL-1 is probably the main inducer of
the seromucoid proteins synthesis and hypoalbumi-
nia. It would appear that TNF has only a minor
role in the production of the seromucoid proteins.
The use of osmotic minipumps to infuse
cytokines into animals has shown that greater effects
can be obtained with ’low’ concentrations of
cytokines and also that this method may be
physiologically more relevant than single bolus
dose since in inflammatory conditions cytokines
would be released continuously over the period of
the inflammation.
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